| [1] Kim S Y, Peng Z H, Kaneda Y F, et al. Current status of gene therapy in Asia. Mol Ther, 2008, 16(2): 237-243.
[2] Wonganan P, Croyle M A. PEGylated adenoviruses: from mice to monkeys. Viruses, 2010, 2, 468-502.
[3] Clinical Trial sita Vectors used in gene therapy clinical trial. http://www.abedia.com/wiley/vectors.php.
[4] Oliver M T, Kerry D F, Julia H, et al. Glycoviruses: chemical glycosylation retargets adenoviral gene transfe. Angew Chem Int Ed, 2005, 44: 1057-1061.
[5] O'Riordan C R, Lachapelle A, Delgado C, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther, 1999, 10: 1349-1358.
[6] Cheng X, Ming X, Croyle M A. PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route. Pharm Res, 2003, 20(9): 1444-1451.
[7] Croyle M A, Chirmule N, Zhang Y, et al. PEGylation of E1-Deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther, 2002, 13: 1887-1900.
[8] Hoyin M, Donna J P, Philip N, et al. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther, 2005, 11: 66-79.
[9] Wortmann A, Vhringer S, Engler T, et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther, 2008, 16: 154-162.
[10] Hofherr S E, Shashkova E V, Weaver E, et al. Modification of adenoviral vectors with polyethylene glycol modulates In vivo tissue tropism and gene expression. Mol Ther, 2008, 16: 1276-1282.
[11] Danielsson A, Elgue G, Nilsson B M, et al. An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood. Gene Ther, 2010, 17: 1-11.
[12] Ji W P, Hyejung M, Tae G P. Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J Cont Rel, 2010, 142: 238-244.
[13] Ji W P, Hyejung M, Tae G P. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochem Bioph Res Co, 2008, 366: 769-774.
[14] Jung Y Y, Park H, Kim P-H, et al. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. J Cont Rel, 2007, 123: 164-171.
[15] Oh I K, Mok H, Park T G. Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. Bioconjugate Chem, 2006, 17: 721-727.
[16] Yao X, Yoshioka Y, Morishige T, et al. Adenovirus vector covalently conjugated to polyethylene glycol with a cancer-specific promoter suppresses the tumor growth through systemic administration. Biol Pharm Bull, 2010, 33(6): 1073-1076.
[17] Blanka R. Biocompatibility and immunocompatibility of water-soluble polymers based on HPMA. Composites: Part B, 2007, 38: 386-397.
[18] Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther, 2008, 16: 16-29.
[19] Karel U, Vladimír . Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliver Rev, 2010, 62: 150-166.
[20] Subr V, Ulbrich K. Synthesis and properties of new N-(2-hydroxypropyl)-methacrylamide copolymers containing thiazolidine-2-thione reactive groups. React Funct Polym, 2006, 66: 1525-1538.
[21] Fisher K D, Stallwood Y, Green N K, et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralizing antibodies. Gene Ther, 2001, 8: 341-348.
[22] Robert C, Carlisle Y D, Anna M C, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood, 2009, 113: 1909-1918.
[23] Vladimir S, Libor K, Tom S M, et al. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J Cont Rel, 2009, 135: 152-158.
[24] Green N K, Herbert C W, Hale S J, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther, 2004, 11: 1256-1263.
[25] Morrison J, Briggs S S, Green Nicola. Virttherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol Ther, 2007, 16: 244-251.
[26] Green N K, Morrison J, Hale S. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J. Gene Med, 2008, 10: 280-289.
[27] Fisher K D, Green N K, Hale H, et al. Passive tumor targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target, 2007, 15: 546-551.
[28] Kasman L M, Barua S, Lu P, et al. Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. Molecular Pharmaceutics, 2009, 6(5): 1612-1619.
[29] Han J F, Zhao D, Zhong Z R, et al. Combination of adenovirus and cross-linked low molecular weight PEI improves efficiency of gene transduction. Nanotechnology, 2010, 21(10): 1-10.
[30] Espenlaub S, Wortmann A, Engler T, et al. Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides. J Gene Med, 2008, 10: 1303-1314.
[31] Park Y, Eunah Kang, Kwon O J, et al. Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy. J Cont Rel, 2010, 148: 75-82.
[32] Wang I J, Jhuang M C, Chen Y H, et al. Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells. Plos One, 2010, 5: 1-10.
[33] Harding S E. Mucoadhesive interactions. Biochem Soc Trans, 2003, 31: 1036-1041.
[34] Stevenson M, Boos E, Herbert C, et al. Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells. Gene Ther, 2006, 13: 356-368.
[35] Robert C C, Reuben B, Simon S B, et al. Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralizing antisera. J Gene Med, 2008, 10: 400-411. |
